Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib with intra-articular injection strategies for knee osteoarthritis
IRCT20190114042360N1Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of celecoxib, methylprednisolone and hyaluronic acid in osteoarthritis (OA) (4 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Pain, Visual analog scale at 3 weeks and 2 more. Started Jun 2019; status: completed.
02
Drugs
celecoxibmethylprednisolonehyaluronic acid
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on IRCT20190114042360N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190114042360N1.